Tag:
Dainippon Sumitomo
Latest Headlines
Latest Headlines
Dainippon Sumitomo inks $545M-plus orphan drug R&D pact with Edison
Edison Pharmaceuticals shed its stealth mode and went public with a $545 million-plus collaboration deal with Japan's Dainippon Sumitomo that centers on its lead late-stage drug for rare diseases.
Intercept Pharma files for $75M IPO to back PhIII liver drug
Just days after rounding up $30 million in venture cash, New York-based Intercept Pharmaceuticals is boldly gambling that investors will cough up about $75 million to buy into a late-stage orphan drug for chronic liver disease. The biotech filed for an ambitious IPO, hoping it can avoid the price cuts that most other such development-stage biotech bids have been forced to endure in recent years.
Nitto Denko, Dainippon begin Phase II for world's first transdermal antipsychotic
Nitto Denko and Dainippon Sumitomo have started a Phase II trial of a transdermal patch delivering Dainippon Sumitomo's antipsychotic Lonasen (blonanserin), which has been launched in Japan and South Korea.
Dainippon bags Boston Biomedical and cancer stem cell tech in $2.6B buyout
Boston Biomedical's focus on targeting cancer stem cells has paid off.
Chelsea Therapeutics reports positive efficacy results in PhII fibromyalgia study
Chelsea Therapeutics ( $CHTP ) has racked up some more positive efficacy data for its lead drug droxidopa , which is now up for review at the FDA. Investigators reported the drug spurred a statistically
Sunovion's inhaled steroid for allergies looks good in Ph3 amid FDA review
While the FDA reviews its application for approval of the experimental drug, Sunovion Pharmaceuticals revealed upbeat data from a major Phase III trial of its ciclesonide nasal aerosol against...
Intercept lands $315M Asian pact for liver disease drug
Japan's Dainippon Sumitomo is slapping down $15 million and promising up to $300 million more in milestones in exchange for the rights to Intercept Pharmaceuticals' late-stage liver disease drug in
FDA approves Dainippon's Latuda for schizophrenia
The FDA has given the green light to Dainippon Sumitomo Pharma's Latuda ( lurasidone ), an atypical antipsychotic. The drug is designed to work like other atypcals such as Zyprexa, Risperdal or
FDA declines to approve Dainippon's epilepsy drug
Last fall, when Dainippon Sumitomo Pharma announced that it had inked a deal to buy Sepracor for $2.6 billion , the Japanese pharma company cited the once-daily epilepsy drug Stedesa as one of the
Sepracor merges and CEO Adams jumps to Inspire
With the $2.6 billion acquisition of Sepracor by Dainippon Sumitomo drawing to a close soon, the developer's CEO is on his way over to take the helm at Raleigh, NC-based Inspire Pharmaceuticals.
